Barzolvolimab

Recent clinical trials demonstrate that emerging therapies including dupilumab, remibrutinib, and barzolvolimab achieve complete response rates of 28-51% in patients with chronic spontaneous urticaria (CSU) who are resistant to standard treatments.

Longbio's LP-003 demonstrated superior improvement in UAS7 scores compared to Omalizumab at weeks 4 and 12 in Phase II trial for Chronic Spontaneous Urticaria treatment.

Celldex Therapeutics reports significant progress in Phase 3 trials of barzolvolimab for chronic spontaneous urticaria (CSU), with active enrollment ongoing across 40 countries and 500 sites.

The global chronic spontaneous urticaria (CSU) market is projected to grow from $15.1 million in 2024 to $36 billion by 2035, driven by rising diagnosis rates and innovative biologic therapies.

Celldex Therapeutics has begun a Phase 2 clinical trial to evaluate barzolvolimab for treating moderate to severe atopic dermatitis, a chronic inflammatory skin condition.